Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NCM – Цена в реальном времени. Валюта: USD

11.43

+0.39 (3.53%)

При закрытии: May 12, 2026, 4:00 PM EDT

11.27

-0.16 (-1.40%)

До открытия: May 13, 2026, 8:36 AM EDT

05.05.2026

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that it will host an in-person and virtual KOL event at the 2026 American Society of Clinical Oncology (ASCO) annual meeting to discuss updated data from the Phase 1/2 clinical study of CRB-701 in 75 participants with head and neck squamous cell carcinoma (HNSCC).

07.04.2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment.

11.03.2026

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

09.03.2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025.

12.02.2026

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026.

15.01.2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

05.01.2026

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.

Видео

No Data

There is no data to display

Пресс-релизы

05.05.2026

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

09.03.2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

11.12.2025

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("CANYON-1"), with completion expected in summer 2026. CRB-913 is a highly peripherally restricted oral small molecule CB1 inverse agonist targeting chronic obesity management.

31.10.2025

Corbus Pharmaceuticals Announces Pricing of Public Offering

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total public offering size of approximately $75 million, before deducting underwriting discounts and estimated offering expenses.

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Corbus Pharmaceuticals Announces Pricing of Public Offering

Search stocks

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Видео

No Data

Пресс-релизы

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Corbus Pharmaceuticals Announces Pricing of Public Offering